Synthetic Methods for the Preparation of Platinum Anticancer Complexes
Name
Lippard_Synthetic methods.pdf
Size
3.28 MB
Format
Adobe PDF
Checksum (MD5)
90afd5c45ea6860b4eb853421fda629c
Author(s)
Wilson, Justin J.
Lippard, Stephen J.
Date Issued
November 2013
Journal
Chemical Reviews
Publisher
American Chemical Society (ACS)
Citation
Wilson, Justin J., and Stephen J. Lippard. “Synthetic Methods for the Preparation of Platinum Anticancer Complexes.” Chemical Reviews 114, no. 8 (April 23, 2014): 4470–4495.
Version
Author's final manuscript
Abstract
The demonstration in the 1960s that cis-diammine-dichloroplatinum(II), or cisplatin, inhibits cellular division of Escherichia coli led to the subsequent discovery that this simple coordination compound is also an effective antitumor agent in mouse models. Subsequent studies validated cisplatin as an effective anticancer agent in humans as well, and FDA approval of cisplatin for the treatment of metastatic ovarian and testicular cancers was granted in 1978. Its introduction as a chemotherapeutic agent significantly improved the survival outlook for many cancer patients; the cure rate for testicular cancer before the approval of cisplatin was less than 10%, significantly lower than the 90% cure rate attained with modern platinum chemotherapy.
MIT Department
Massachusetts Institute of Technology. Department of Chemistry
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1021/cr4004314
